Triple Negative Breast Neoplasms: all 1,163 studies

Page 10 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1
• CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast CancerStatus unknownNCT04059003
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• Study on Bisphosphonates Targeting Triple-negative Breast CancerStatus unknownNCT04045522
• Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)CompletedNCT04031703Phase 3
• Screening Magnetic Resonance Imaging of the Brain in Patients With Breast CancerActive, not recruitingNCT04030507Not applicable
• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
• Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT04024800Phase 2
• A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCompletedNCT03997968Phase 1/2
• Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive, not recruitingNCT03997123Phase 3
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWithdrawnNCT03982173Phase 2
• Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast CancerCompletedNCT03981705
• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedNCT03979508Phase 2
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaActive, not recruitingNCT03961698Phase 2
• A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingNCT03945721Phase 1
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
• Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast CancerStatus unknownNCT03932526Phase 2
• Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsActive, not recruitingNCT03915678Phase 2
• Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersActive, not recruitingNCT03911973Phase 1/2
• Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast CancerStatus unknownNCT03907800Phase 2
• A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03893955Phase 1
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBCActive, not recruitingNCT03881605Not applicable
• The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyStatus unknownNCT03876886Phase 3
• A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedNCT03872791Phase 1/2
• Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerWithdrawnNCT03872505Phase 2
• A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsTerminatedNCT03861403Phase 1
• A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)Status unknownNCT03855358Phase 1
• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersCompletedNCT03829436Phase 1
• Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2
• Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastActive, not recruitingNCT03812393Phase 2
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and LungActive, not recruitingNCT03808662Phase 2
• FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
• Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast CancerStatus unknownNCT03799679Phase 4
• A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast CancerWithdrawnNCT03794596Phase 2
• A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBCSuspendedNCT03777579Phase 3
• Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast CancerStatus unknownNCT03775928Phase 2
• A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsCompletedNCT03775850Phase 1
• Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT03756298Phase 2
• Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)CompletedNCT03752723Phase 1/2
• A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).TerminatedNCT03742349Phase 1
• Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast CancerStatus unknownNCT03735082Phase 2
• TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast CancerStatus unknownNCT03720431Phase 1
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
• Leflunomide in Previously Treated Metastatic Triple Negative CancersCompletedNCT03709446Phase 1/2
• Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast CancerStatus unknownNCT03692689Phase 2
• Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)TerminatedNCT03674242Phase 2/3
• COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.CompletedNCT03667716Phase 1
• Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerCompletedNCT03654547Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of TreatmentStatus unknownNCT03650738Phase 2
• Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerWithdrawnNCT03644589Phase 2
• Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast CancerWithdrawnNCT03634150Phase 1/2
• Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast CancerStatus unknownNCT03617341
• Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCActive, not recruitingNCT03616886Phase 1/2
• Emotions Immunology and Breast CancerCompletedNCT03609671Not applicable
• Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedNCT03599453Early Phase 1
• NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyActive, not recruitingNCT03589339Phase 1
• Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast CancerCompletedNCT03586297
• M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerTerminatedNCT03579472Phase 1
• Effect of Bevacizumab in Metastatic Triple Negative Breast CancerCompletedNCT03577743Phase 2
• Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCActive, not recruitingNCT03567720Phase 2
• Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCActive, not recruitingNCT03562637Phase 3
• QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnNCT03554109Phase 2
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.TerminatedNCT03549000Phase 1
• Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1
• Triple-negative Breast Cancer: a New Perspective on BiomarkersCompletedNCT03539965
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)CompletedNCT03504488Phase 1/2
• Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerWithdrawnNCT03473691Early Phase 1
• Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerCompletedNCT03464942Phase 2
• Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast CancerCompletedNCT03457779Not applicable
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedNCT03454451Phase 1
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
• Neoadjuvant Goserelin for Triple Negative Breast CancerStatus unknownNCT03444025Phase 2
• S 81694 Plus Paclitaxel in Metastatic Breast CancerCompletedNCT03411161Phase 1/2
• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingNCT03401385Phase 1
• PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast CancerActive, not recruitingNCT03362060Phase 1
• Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBCTerminatedNCT03361800Early Phase 1
• Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast CancerCompletedNCT03358017Phase 2
• the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line TreatmentTerminatedNCT03358004Phase 2
• Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.CompletedNCT03356860Phase 1/2
• Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast CancerStatus unknownNCT03348098Phase 2
• A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid TumorsTerminatedNCT03343613Phase 1
• Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam ScanningWithdrawnNCT03340402Not applicable
• Clinical Study on Triple Negative Breast Cancer With Chinese MedicineStatus unknownNCT03332368
• A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCCTerminatedNCT03318562Phase 2
• A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)TerminatedNCT03316794Phase 1
• Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP RegimenCompletedNCT03304756Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
• Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboActive, not recruitingNCT03281954Phase 3
• A First-in-Human Study of CAN04 in Patients With Solid Malignant TumorsCompletedNCT03267316Phase 1/2
• PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsStatus unknownNCT03251313Phase 1
• Evaluation of Epalrestat in Metastatic Triple-negative Breast CancerTerminatedNCT03244358Phase 2
• Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast CancerCompletedNCT03243838Phase 2

← Triple Negative Breast Neoplasms overview